Quality Management
Last Updated: 25 August 2026
ISO 14971 risk management for medical devices is defined as a lifecycle approach under the international ISO 14971 standard. The implementation of this standard is mandatory for medical devices manufacturers that want to access international markets including FDA, European MDR, and IVDR.
ISO 14971 Risk Management for Medical Devices: Executive Management and Policy Infrastructure
The starting point for developing a medical device company risk management system should be the company's executive management. With ISO 14971 consulting support, the company's executive management needs to develop a corporate framework and allocate adequate resources:
Risk Acceptability Policy: The executive management needs to formulate the risk management policy for the company and identify the risk acceptance criteria. This policy needs to be based on national or regional regulations, applicable international standards, and generally accepted state of the art.
Cross Functional Competence: The management should make sure that the people allocated to the risk management activities are competent and have an adequate qualification record through education and training.
QMS Integration: The risk management activities need to be integrated into the company's Quality Management System like ISO 13485:2016.
Evaluating Systems with an ISO 14971 Gap Analysis
Prior to certification of this framework, most companies carry out an ISO 14971 gap analysis to uncover any compliance gaps. While designing a product for the target market, it becomes imperative for companies to conduct a thorough and documented localized ISO 14971 risk assessment process that involves setting up the boundaries (both qualitative and quantitative) that affect the safety of the device, such as:
Intended Use and Environment: Document the official intended indications for use, the patient population, the intended users, and the intended use environment.
Foreseeable Misuse: In anticipation of misuse in the target market, identify and document all instances of "reasonably foreseeable misuses" because of predictable human behavior.
Technology Scope: This framework applies globally to all technologies, including Software as a Medical Device (SaMD), in vitro diagnostic (IVD) medical devices, as well as the risks involving biocompatibility, data/systems security, electricity, movement, radiation, and usability.
Normative Hazard Sequence Tracking and Estimation
Mandatory Execution of Risk Control Measures After ISO 14971 Risk Analysis
Should the ISO 14971 risk analysis reveal that the hazard exceeds the threshold of acceptability, then the manufacturer will have to institute controls to manage this. The following controls must be considered and applied in a priority order which is not open to negotiations:
Inherent Safety by Design: Removal of hazards through the application of good initial engineering, design parameters, and sound manufacturing practices.
Protective Measures: Use of safety systems, safety barriers, and alarm systems in either the medical device or the manufacturing process.
Information for Safety: Providing warnings, contra indications, labeling, and user instruction through training.
All control measures must be evaluated and demonstrated through objective evidence such as usability engineering studies and process qualifications.
Benefit Risk Analysis and Overall Residual Risk
International regulatory bodies expect manufacturers to strike a balance between safety and clinical utility.
Individual Residual Risk: Where there is an individual residual risk that cannot be controlled and further reduced due to technical unfeasibility, the manufacturer can conduct an official benefit risk assessment using available scientific publications. The device will go through if scientific proof is shown that the clinical benefits exceed the residual risk.
Overall Residual Risk Evaluation: After individual control measures have been finalized, the manufacturer should carry out an overall assessment of the residual risk in relation to the overall clinical benefits of the entire system. If found acceptable, all significant residual risks must be explicitly stated in the documents accompanying the device.
Essential Documentation for ISO 14971 risk management for medical devices: The Risk Management File (RMF)
Constructing an ISO 14971 Risk Management Plan
To be able to show that one can meet all the requirements for successful audit in the target markets, the company needs to create a Risk Management File RMF that will be prepared according to audit-ready requirements. Making an ISO 14971 risk management plan is the first step of the pipeline, often supported by an ISO 14971 2019 risk management plan template.
For creating an ISO 14971 risk management for medical devices compliant RMF, one should provide the following information:
Risk Management Plan: an ISO 14971 risk management plan describing the scope of work, intended use, the assignment of responsibilities, criteria for acceptability, and methods for verification. Usually, a company uses ISO 14971 2019 risk management plan template to prepare this document.
Risk Analysis and Risk Evaluation: the two components together which form Technical Risk Assessment, which is a driver for comprehensive ISO 14971 risk analysis.
Risk Controls: a traceability from hazards to specific design control and test records.
Evaluation of Overall Risk Acceptability: final safety conclusions on the system level.
Risk Management Report: a formal execution review of the plan performed before release into commercial distribution.
Post Market Active Surveillance Frameworks
According to the basic principle of risk management within ISO 14971 standard for medical devices, risk management should not conclude with design transfer or market introduction of a product. International commercialization requires the establishment of a positive feedback cycle for proactive collection and assessment of data in production and post production phases.
The data collection process should include:
Feedback from users, complaints and supply chain data such as weaknesses in third party software components or hardware failure.
Field incidents involving similar medical devices already on the market reported publicly.
Changing consensus on the current state of the art.
In case post market data highlights an unknown hazard, changing risk assessment or change in the state of the art, the manufacturer has to conduct a retrospective analysis using local ISO 14971 gap analysis, update the RMF, assess the effect of the new data on the already marketed products, and then incorporate this into the systematic assessment of the management.
How Morulaa Can Help with ISO 14971 Consulting
Our tailored ISO 14971 consulting for Morulaa HealthTech means that medical devices professionals have access to simplifying ISO 14971 risk management for medical devices standard guidelines. Our products and consultants will help you
Trace owners and history of risk activities.
Link your workflow processes to the project requirements for automated traceability.
Standardize risk assessment using personalized risk models and data centralization.
Create auditable documentation for the Risk Management File.
Provide post market surveillance data feeds directly to active risk files.
Frequently Asked Questions (FAQs)
Is there any acceptable risk level for a medical device in ISO 14971 risk management for medical devices?
No, the standard does not provide you with predefined acceptable risk levels. The top management should set their objective criteria for acceptable risk depending on the situation and application of the device.
Can I rely on Information for Safety as the main risk control measure?
No, you cannot, since there is an unchangeable priority order in the risk controls: first of all, inherently safe design and manufacturing should be applied, then some protective measures (barriers, alarms), and only the last one may be warnings/user training.
What should be included in the Risk Management File RMF prior to commercialization?
RMF is a dynamic record, which provides bidirectional traceability for each hazard. It should include information about the original ISO 14971 risk management plan, the local ISO 14971 risk analysis, verification information about controls, and the legally binding Risk Management Report, which evaluates the implementation of the plan.
Does the risk management process come to an end once a device receives its regulatory approval?
No, it doesn’t because risk management covers the whole product life cycle from the very conception of the idea up until the decommissioning and disposal of the device.
What does the Risk Management Report entail when using an ISO 14971 2019 risk management plan template?
The Risk Management Report is a formal review of your original plan during execution. In order to make the process as efficient as possible, people refer to an ISO 14971 2019 risk management plan template to make sure that the initial criteria align with the final review. This report needs to be completed before releasing a device for commercial distribution and serves as a legally-binding report embedded within the RMF.
How do companies usually start the process of updating their systems according to these regulations?
The majority of companies usually begin with specialized ISO 14971 consulting, which consists of reviewing the company's procedures in the lifecycle. The next step would be conducting the ISO 14971 gap analysis.